A novel study has found that Bimuno GOS, a galactooligosaccharide-based nutraceutical by Clasado Biosciences, demonstrates prebiotic efficacy at a dose of 380mg.
According to the pre-publication research, the prebiotic effect is still statistically significant at this ultra-low dose, highlighting the ingredient's potential in dosage formats down to size 00 capsules.
By exhibiting a prebiotic effect at a low dose, Bimuno GOS can be taken in a single, low-dose format — enhancing user experience and reducing the impact of pill fatigue.
Down from 1.37g to 380mg
In recent years, scientists have uncovered the role of gut health in overall wellbeing, so many researchers in the natural ingredients space have endeavoured to identify gut health-boosting solutions.
Through this research, many have discovered the potential of prebiotic fibres such as galactooligosaccharides, which have been found to promote gastrointestinal, immune and cognitive health, while also assisting users in managing their weight.
"While doses from 1.37g of Bimuno GOS can offer a range of clinically-proven health benefits, this research delivers an important new finding," stated Dr Lucien Harthoorn, R&D Director at Clasado Biosciences.
"By supporting the gut microbiome, Bimuno GOS can — even at remarkably low doses — continue to deliver its core prebiotic functionality," he noted.
During the study, supplementation with 380mg of active galactooligosaccharides increased the prevalence of beneficial Bifidobacterium strains in the gut microbiome, while also enhancing the production of benefical short-chain fatty acids (SCFAs) such as butyrate and acetate.
It also lowered pH levels in the intestines, which is a key marker often associated with prebiotic activity.
Bimuno GOS likely exhibits this effect through its unique structure, according to Dr Harthoorn, which helps it to nourish beneficial gut bacteria and promote their activity.
New formulation opportunities
The findings of this study highlight Bimuno GOS's potential as a low-dose prebiotic, which Clasado believes will change the game for gut health formulators.
"This represents a major advancement for formulators working with specific delivery formats," said Dr Harthoorn.
"Bimuno GOS is now the prebiotic galactooligosaccharide with the lowest effective dose on the market," added Dr Frederic Narbel, VP of Sales at Clasado. "For health brands looking to develop scientifically supported gut health products, Bimuno GOS offers a significant competitive advantage — creating new opportunities in applications where space is limited."
Formulators who are interested in learning more about Bimuno GOS can speak to Clasado at the upcoming Natural Products Expo West event in Anaheim, California this week.